Vendor Intelligence Report: Yiwu Beigong

Published 2 Jul 2026. 18-page investigative report on who is behind Yiwu Beigong: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 4 Finnrick lab tests, Yiwu Beigong has a 75% overall pass rate. The record is narrow: all Finnrick evidence in this dossier sits on Retatrutide, where three passes and one failure make the product a conditional rather than high-confidence choice. The data does not support carrying that confidence over to Tirzepatide, BPC-157, or any Huaian Hanyou-linked substitution.

The bigger buyer issue is identity and accountability. Yiwu Beigong is a WhatsApp-led China-listed seller whose contact path points into the Huaian Hanyou Health Co., Ltd. orbit, while Huaian Hanyou and Huaian Banting Trading share an address and overlapping peptide signals. Formation records and domain chronology also sit uncomfortably beside long operating-history and facility claims.

Operational risk is not hypothetical in the public-source trail. The report reviews a sales-alias thread around Selena, later customer complaints about non-updating tracking and degraded communication, and website-authentication warnings around Huaian Hanyou-linked channels. The affiliate scan is a notable counterweight: swept X and web sources did not surface a Yiwu Beigong coupon or referral network, though several social platforms remained outside scope.

The practical read is directional: Yiwu Beigong is not a no-data vendor, but its usable Finnrick signal is product-specific and too small to override unresolved corporate, website, and fulfillment questions. Buyers considering this route should separate Retatrutide evidence from broader catalog claims and treat payment, channel verification, and batch testing as central controls.

Inside the full report:

  • Entity-resolution table for Yiwu Beigong, Huaian Hanyou Health Co., Ltd., Huaian Banting Trading Co., Ltd., He Fengjie, and Selena
  • Registry and domain timeline comparing corporate formation, domain age, and long-history marketing claims
  • Address-cluster exhibits including ChemicalBook and Finnrick captures for Huaian Banting at No.108 Qianjiang Road
  • Website-authentication review covering WhatsApp routing, invalid SSL, Reddit and BBB scam-warning trail
  • Customer-experience analysis of tracking-number complaints, post-payment communication degradation, and a Bitcoin non-delivery allegation
  • Retatrutide trajectory, methodology-sensitivity chart, and Appendix A — Finnrick Laboratory Data

Risk assessment

  • Corporate identity opacity — high: Yiwu Beigong is a recent, contact-led brand linked by directory/contact evidence to Huaian Hanyou, while Huaian Hanyou and Huaian Banting share address/name-network signals.
  • Order-fulfillment and tracking-integrity risk — high: Customer reports allege fake or non-updating tracking numbers, post-payment communication degradation, blocking or ghosting, and at least one Bitcoin non-delivery case.
  • Website and brand-authentication risk — high: yiwubeigong.com was registered 2026-03-23 and showed an invalid SSL certificate; Huaian Hanyou-related web channels carried Reddit/BBB scam warnings and no clear authenticity controls surfaced.
  • Manufacturing and certification verification gap — medium: Claims of a 3,000 m2 GMP/ISO-certified facility and 60–79 employees were not independently verified; the shared address with Huaian Banting leaves reseller or common-office scenarios open.
  • Retatrutide quality-consistency risk — medium: Only Retatrutide has Finnrick data for Yiwu Beigong: 4 tests, 3 pass / 1 fail, current rating 78.6%, leaving other products ungraded and Retatrutide a conditional rather than strong choice.